AVBP

ArriVent BioPharma's stock has been influenced by several events in the past six months. The company's Q4 2025 earnings surpassed estimates, and analysts increased price targets with "buy" or "overweight" ratings. The topline data readout for the Phase 3 FURVENT trial was delayed. ArriVent dosed the first patient for ARR-217, advancing its ADC pipeline. Institutional investors increased their stakes in ArriVent BioPharma during Q4 2025. The company's share price has outperformed the S&P500 Index by +20.95% and reached a new 52-week high in April 2026, increasing by 46.6% since the start of the year. Shares rallied approximately 75% since August 2025, in anticipation of positive results from a pivotal trial for EGFR mutant NSCLC in mid-2026. On May 7, 2026, ArriVent announced IND clearance for ARR-002. In March 2026, ArriVent presented preclinical posters on firmonertinib and ARR-002 at the AACR Annual Meeting and reported its Full Year 2025 Financial Results. FMR LLC disclosed a 6.8% stake in ArriVent BioPharma on May 6, 2026. Competitive risk in the EGFR exon 20 insertion mutation indication increased following Dizal Pharmaceuticals' reported Phase 3 success with its therapy Zegfrovy.